JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Tel: +1-832-696-8203
Email: [email protected]
Worldwide Distributors
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Cell lines
Rat primary hepatic stellate cells (HSCs)
Reaction Conditions
500 μmol/L camostat mesilate for 7 d incubation
Applications
Camostat mesilate (500 μmol/L) inhibited generation of transforming growth factor β (TGF-β) by suppressing plasmin activity and reduced the activity of TGF-β, which blocked in vitro activation of HSCs.
Animal models
Male Wistar rats
Dosage form
1 ~ 2 mg/g
Diet
Camostat mesilate (1 ~ 2 mg/g of diet) markedly attenuated an increase in hepatic plasmin and TGF-β levels, HSC activation, and hepatic fibrosis without apparent systemic or local side effects in porcine serum-treated rats. Therefore, camostat mesilate prevented porcine serum-induced rat hepatic fibrosis via a profound reduction in TGF-β generation
Note
The technical data provided above is for reference only.
References:
1. Okuno M, Akita K, Moriwaki H, et al. Prevention of rat hepatic fibrosis by the protease inhibitor, camostat mesilate, via reduced generation of active TGF-beta. Gastroenterology, 2001, 120(7): 1784-1800.